Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00962039 · ClinicalTrials.gov registry record · Phase 2

Anxiety and Recurrent Abdominal Pain in Children

A Phase 2 study of Anxiety and Abdominal Pain, sponsored by John V. Campo, M.D..

Completed
Registry status
Phase 2
Development phase
81
Enrollment target
1
Study location

NCT00962039 is a Phase 2 study of Anxiety and Abdominal Pain that has completed, run by John V. Campo, M.D.. The registered enrollment target is 81 participants, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00962039, a Phase 2 study of Anxiety and Abdominal Pain, has completed, sponsored by John V. Campo, M.D..

COMPLETED
Registry status
Phase 2
Development phase
81 participants
Enrollment target
1
Study location

Study Summary

This study aims to determine whether citalopram is a useful, well-tolerated, and safe treatment for children and adolescents ages 7 to 18 years with functional abdominal pain. The study hypothesis is that citalopram will be better than placebo in producing clinical improvement and reductions in abdominal pain. It is also hypothesized that citalopram and placebo will not differ in terms of safety and tolerability.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Citalopram

Study Locations (1)

Ohio

  • The Research Institute at Nationwide Children's Hospital - Columbus

Trial Details

FieldValue
Enrollment Target 81 participants
Start Date 2004-07
Est. Completion 2010-04
Phase Phase 2

Sponsor

John V. Campo, M.D.

1 total trials

What the Registry Record Tells You About NCT00962039

The ClinicalTrials.gov registry entry for NCT00962039 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (82% lower). The listed sponsor is John V. Campo, M.D., which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Anxiety appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00962039 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT00962039 about?

NCT00962039 is a clinical study titled "Anxiety and Recurrent Abdominal Pain in Children". This study aims to determine whether citalopram is a useful, well-tolerated, and safe treatment for children and adolescents ages 7 to 18 years with functional abdominal pain. The study hypothesis is that citalopram will be better than placebo in producing clinical improvement and reductions in abdo...

What is the current status of trial NCT00962039?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2004-07. Estimated completion is 2010-04.

What conditions does trial NCT00962039 study?

This clinical trial studies the following conditions: Anxiety, Abdominal Pain.

What interventions are being tested in trial NCT00962039?

The interventions under investigation include: Placebo (DRUG), Citalopram (DRUG).

Who is sponsoring clinical trial NCT00962039?

This trial is sponsored by John V. Campo, M.D., which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00962039 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Anxiety

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.